NMTR Insider Trading
Insider Ownership Percentage: 2.40%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
9 Meters Biopharma Insider Trading History Chart
This chart shows the insider buying and selling history at 9 Meters Biopharma by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
9 Meters Biopharma Share Price & Price History
Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 04/8/2025 01:00 AM ET
9 Meters Biopharma Insider Trading History
9 Meters Biopharma Institutional Trading History
Data available starting January 2016
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.
Read More on 9 Meters Biopharma
Today's Range
Now: N/A
50 Day Range
MA: N/A
52 Week Range
Now: N/A
Volume
N/A
Average Volume
315,915 shs
Market Capitalization
$1.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.36
Who are the company insiders with the largest holdings of 9 Meters Biopharma?